Company: NGVT
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001653477-25-000108
Chunk: 48

Company: Ingevity Corp
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 48
---
 specifically managed as part of one specific segment herein referred to as "Corporate and other."

Note 15: Earnings (Loss) per Share

Three Months Ended June 30,Six Months Ended June 30,In millions (except share and per share data)2025202420252024Net income (loss) $(146.5)$(283.7)$(126.0)$(339.7)Basic and Diluted earnings (loss) per shareBasic earnings (loss) per share $(4.02)$(7.81)$(3.46)$(9.36)Diluted earnings (loss) per share (4.02)(7.81)(3.46)(9.36)Shares (in thousands)Weighted average number of common shares outstanding - Basic36,461 36,335 36,422 36,299 Weighted average additional shares assuming conversion of potential common shares— — — — Shares - diluted basis (1)36,461 36,335 36,422 36,299 _______________(1) For the three and six months ended June 30, 2025 and 2024, all potentially dilutive common shares were excluded from the calculation of diluted earnings (loss) per share as we had a net loss for the period. The following average number of potential common shares were antidilutive, and therefore, were not included in the diluted earnings per share calculation:Three Months Ended June 30,Six Months Ended June 30,In thousands2025202420252024Average number of potential common shares - antidilutive438 198 368 229 

27

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Introduction

Management’s discussion and analysis of Ingevity Corporation's (“Ingevity,” “the company,” “we,” “us,” or “our”) financial condition and results of operations (“MD&A”) is provided as a supplement to the Condensed Consolidated Financial Statements and related notes included elsewhere herein to help provide an understanding of our financial condition, changes in financial condition and results of our operations. The following discussion should be read in conjunction with Ingevity’s consolidated financial statements as of and for the year ended December 31, 2024, filed on February 19, 2025, with the Securities and Exchange Commission ("SEC") as part of the company's Annual Reporting on Form 10